Exisulind

Chemical Compound
Identifiers
CAS Number
PubChem CID
ChemSpider ID
UNII
ChEBI
ChEMBL
Properties
Chemical Formula
Molar Mass
Appearance
Density
Melting Point
Boiling Point
Hazards
GHS Pictograms	[[File:|50px]]
GHS Signal Word
GHS Hazard Statements
NFPA 704	[[File:|50px]]
References

Exisulind (tentative trade name Aptosyn) is an antineoplastic agent. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase type 5 (EC 3.1.4.17 ).<ref>,

 Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone., 
 Drugs in R&D, 
 
 Vol. 5(Issue: 4),
 pp. 220–6,
 
 PMID: 15230629,</ref> It is the sulfone derivative of sulindac, an NSAID. Unlike sulindac, it has known effects on prostaglandin synthesis.<ref>, 
 Phase I trial of Exisulind (Sulindac Sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis., 
 Clinical Cancer Research, 
 
 Vol. 6(Issue: 1),
 pp. 78–89,
 
 PMID: 10656435,</ref> It was developed as the potential treatment of several conditions including familial adenomatous polyposis (FAP), precancerous sporadic colonic polyps, cervical dysplasia and the prevention of tumor recurrence in prostate and breast cancer.<ref>, 
 Exisulind Cell Pathways., 
 Current Opinion in Investigational Drugs, 
 
 Vol. 1(Issue: 3),
 pp. 386–91,
 
 PMID: 11249724,</ref> Exisulind inhibits the enzyme cGMP-PDE, overexpressed in precancerous and cancerous colorectal cells, and induces apoptosis in such cells with minimal effects on normal cells. This apoptotic effect is independent of COX-1 or COX-2 inhibition, p53, Bcl-2, or cell cycle arrest. Preclinical evidence suggests that exisulind also inhibits angiogenesis.<ref>, 
 Inhibition of Angiogenesis by Sulindac and its Sulfone Metabolite (FGN-1): a Potential Mechanism for Their Antineoplastic Properties., 
 International Journal of Tissue Reactions, 
 
 Vol. 20(Issue: 3),
 pp. 85–9,
 
 PMID: 9894180,</ref>

See also

• Sulindac

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia